Jones Financial Companies
SLXN

Jones Financial Companies’s Silexion Therapeutics SLXN Stock Holding History

Jones Financial Companies’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$32 – 5191
2026
Q1 		$32 Hold
3
– – ﹤0.01% 4683
2025
Q4 		$50 Buy
+3
New +$90 ﹤0.01% 4341

Other funds holding SLXN

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Jones Financial Companies's SLXN Position: Q2 2026 in Review

Jones Financial Companies sold out of Silexion Therapeutics (SLXN) in Q2 2026, closing a stake of 3 shares — an estimated $32 sold.

Jones Financial Companies first reported a position in SLXN in Q4 2025 and held it in 2 quarters. The position peaked at $50 in Q4 2025. 6 funds tracked by Wall St. Rank hold SLXN as of Q2 2026.

  • Jones Financial Companies reported no remaining Silexion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jones Financial Companies sold 3 Silexion Therapeutics shares in Q2 2026, an estimated $32.
  • Jones Financial Companies first reported a position in Silexion Therapeutics in Q4 2025 and held it in 2 quarters.
  • Jones Financial Companies's Silexion Therapeutics position peaked at $50 in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.